Contextual linking between workflow provenance and system performance logs

When executing scientific workflows, anomalies of the workflow behavior are often caused by different issues such as resource failures at the underlying infrastructure. The provenance information collected by workflow management systems only captures the transformation of data at the workflow level. Analyzing provenance information and apposite system metrics requires expertise and manual effort. Moreover, it is often timeconsuming to aggregate this information and correlate events occurring at different levels of the infrastructure. In this paper, we propose an architecture to automate the integration among workflow provenance information and performance information from the infrastructure level. Our architecture enables workflow developers or domain scientists to effectively browse workflow execution information together with the system metrics, and analyze contextual information for possible anomalies

EULAR study group on 'MHC-I-opathy':identifying disease-overarching mechanisms across disciplines and borders

The 'MHC-I (major histocompatibility complex class I)-opathy' concept describes a family of inflammatory conditions with overlapping clinical manifestations and a strong genetic link to the MHC-I antigen presentation pathway. Classical MHC-I-opathies such as spondyloarthritis, Behçet's disease, psoriasis and birdshot uveitis are widely recognised for their strong association with certain MHC-I alleles and gene variants of the antigen processing aminopeptidases ERAP1 and ERAP2 that implicates altered MHC-I peptide presentation to CD8+T cells in the pathogenesis. Progress in understanding the cause and treatment of these disorders is hampered by patient phenotypic heterogeneity and lack of systematic investigation of the MHC-I pathway.Here, we discuss new insights into the biology of MHC-I-opathies that strongly advocate for disease-overarching and integrated molecular and clinical investigation to decipher underlying disease mechanisms. Because this requires transformative multidisciplinary collaboration, we introduce the EULAR study group on MHC-I-opathies to unite clinical expertise in rheumatology, dermatology and ophthalmology, with fundamental and translational researchers from multiple disciplines such as immunology, genomics and proteomics, alongside patient partners. We prioritise standardisation of disease phenotypes and scientific nomenclature and propose interdisciplinary genetic and translational studies to exploit emerging therapeutic strategies to understand MHC-I-mediated disease mechanisms. These collaborative efforts are required to address outstanding questions in the etiopathogenesis of MHC-I-opathies towards improving patient treatment and prognostication.Publisher PDFPeer reviewe